8-Bromo-3-methyl-1H-purine-2,6(3H,7H)-dione

We are 8-Bromo-3-methyl-1H-purine-2,6(3H,7H)-dione CAS:93703-24-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   8-Bromo-3-methyl-1H-purine-2,6(3H,7H)-dione
CAS.NO:  93703-24-3
Synonyms:
8-bromo-3-methyl-7H-purine-2,6-dione
8-Bromo-3-methyl-3,7-dihydro-1H-purine-2,6-dione
8-BroMo-3-Methyl-xanthine
2H-purin-2-one, 8-bromo-3,7-dihydro-6-hydroxy-3-methyl-
1H-Purine-2,6-dione, 8-bromo-3,7-dihydro-3-methyl-

Molecular Formula:  C6H5BrN4O2
Molecular Weight:  245.03300

Physical and Chemical Properties:
Density: 1.975 g/cm3
Boiling point: /
Melting point:300°C(lit.)
Flash point: /
Refractive index: 1.662

Specification:
Appearance: White powder
Purity:≥99.0%
Specific rotation:+39.5 to +41.5°
State of solution(transmittance) :Clear98.0% min.
Chloride[cl] :0.020% max.
Ammonium [NH4] :0.02% max.
Sulfate[SO4] :0.020% max
Iron[Fe] :10ppm max.
Heavy metals [Pb] :10ppm max
Arsenic[As2O3] :1ppm max
Other amino acids :Chromatographically not detectable
Loss on drying :0.20% max.
Residue on ignition[sulfated] :0.10% max.

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Keep container tightly closed in a cool, dry place.
Application: 8-Bromo-3,9-dihydro-3-methyl-1H-purine-2,6-dione, is a substituted derivative of of Xanthine, found in animal organs, yeast, potatoes, coffee beans, tea. It can also be used for the synthesis of Linagliptin, which is a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes. Intermediates of Linagliptin  CAS:668270-12-0.

Related News: At the same time, due to the relatively late development of the bulk drug business in China, most of the established bulk drug companies are currently in the field of commonly used generic drug bulk drugs. Stand up.884495-23-2 However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.2,4-Dichloropyrimidine CAS:3934-20-1 Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.99-57-0 There are however certain APIs that are unknown and so require additional substances that work in conjunction with the API to produce the required effect.China has a complete upstream and downstream industry chain, lower costs, and good talent reserves. It is one of the few industries in China that has an advantage in international competition.